Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $2,296,745.48 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig E. Hunsaker sold 186,122 shares of the firm’s stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total value of $2,296,745.48. Following the completion of the transaction, the executive vice president now owns 1,463,896 shares of the company’s stock, valued at approximately $18,064,476.64. This represents a 11.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Alphatec Trading Up 2.3%

Alphatec stock opened at $12.73 on Monday. The stock has a market cap of $1.86 billion, a PE ratio of -9.95 and a beta of 1.10. The stock has a 50-day moving average price of $11.52 and a 200 day moving average price of $10.77. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $13.14. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $169.18 million for the quarter, compared to analysts’ expectations of $167.57 million. During the same quarter in the prior year, the business posted ($0.34) EPS. The company’s revenue for the quarter was up 22.2% compared to the same quarter last year. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ATEC. Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Piper Sandler restated an “overweight” rating and issued a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Alphatec has a consensus rating of “Moderate Buy” and an average target price of $17.89.

Institutional Trading of Alphatec

A number of hedge funds have recently added to or reduced their stakes in the business. Nuveen LLC acquired a new stake in Alphatec in the 1st quarter worth about $135,874,000. Vanguard Group Inc. boosted its stake in Alphatec by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock worth $60,990,000 after buying an additional 45,792 shares during the last quarter. American Century Companies Inc. boosted its stake in Alphatec by 16.9% in the 1st quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock worth $59,117,000 after buying an additional 840,974 shares during the last quarter. Royal Bank of Canada boosted its stake in Alphatec by 10.8% in the 1st quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock worth $35,773,000 after buying an additional 342,656 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its stake in shares of Alphatec by 78.4% in the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company’s stock valued at $23,730,000 after purchasing an additional 1,136,330 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.